Integrated Care of Anemia in Chronic Kidney Disease Patients: Concepts in Intravenous Iron Management: Part One

Chronic kidney disease (CKD) has become a worldwide public health issue with increasing prevalence in the United States. As kidney function declines, anemia or other complications may arise, and hemodialysis (HD) or kidney transplantation may be needed. Early intervention and treatment of CKD complications will improve clinical outcomes and may delay or prevent disease sequelae. Primary or adjuvant iron replacement in CKD patients with anemia is recommended. The National Kidney Foundation guidelines state that patients receiving erythropoiesis-stimulating agent (ESA) therapy and HD will require intravenous (IV) iron for optimal iron stores and ESA efficacy. This article, the first of a two-part series, details the optimization of IV iron therapy in CKD patients, clinical trial evaluation of IV versus oral iron in the non–HD-dependent CKD patient, and a comparison of the four available IV iron agents. The percent changes in ESA utilization in conjunction with iron therapy and the associated cost savings are also addressed. The second article in this series goes on to describe elements of the medication use process for care of CKD patients with anemia.